SIAU
VIR icon

SB Investment Advisers (UK)’s Vir Biotechnology VIR Stock Holding History

SB Investment Advisers (UK)’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$98.1M Sell
10,948,093
-2,168,884
-17% -$17.3M 1.27% 5
2025
Q4 		$79.1M Sell
13,116,977
-3,567,064
-21% -$21.2M 0.79% 7
2025
Q3 		$95.3M Hold
16,684,041
– – 0.72% 8
2025
Q2 		$84.1M Hold
16,684,041
– – 0.67% 7
2025
Q1 		$108M Hold
16,684,041
– – 0.99% 6
2024
Q4 		$122M Hold
16,684,041
– – 1.08% 7
2024
Q3 		$125M Hold
16,684,041
– – 1.03% 8
2024
Q2 		$148M Hold
16,684,041
– – 1.37% 7
2024
Q1 		$169M Hold
16,684,041
– – 1.67% 7
2023
Q4 		$168M Hold
16,684,041
– – 1.49% 8
2023
Q3 		$156M Hold
16,684,041
– – 1.29% 7
2023
Q2 		$409M Sell
16,684,041
-1,635,897
-9% -$41.1M 3.12% 6
2023
Q1 		$426M Sell
18,319,938
-1,939,597
-10% -$49.6M 3.5% 7
2022
Q4 		$513M Sell
20,259,535
-1,826,745
-8% -$44.8M 4.28% 5
2022
Q3 		$426M Sell
22,086,280
-130,364
-0.6% -$3.31M 3.26% 5
2022
Q2 		$566M Hold
22,216,644
– – 4.5% 4
2022
Q1 		$571M Hold
22,216,644
– – 2.71% 7
2021
Q4 		$930M Sell
22,216,644
-400,022
-2% -$15.7M 2.71% 7
2021
Q3 		$984M Hold
22,616,666
– – 3.05% 5
2021
Q2 		$1.07B Hold
22,616,666
– – 2.1% 7
2021
Q1 		$1.16B Hold
22,616,666
– – 2.01% 6
2020
Q4 		$606M Hold
22,616,666
– – 2.44% 6
2020
Q3 		$776M Hold
22,616,666
– – 6.67% 4
2020
Q2 		$927M Hold
22,616,666
– – 10.1% 3
2020
Q1 		$775M Hold
22,616,666
– – 8.35% 3
2019
Q4 		$284M Buy
+22,616,666
New +$303M 3.12% 4

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SB Investment Advisers (UK)'s VIR Position: Q1 2026 in Review

SB Investment Advisers (UK) reduced its Vir Biotechnology (VIR) stake by 17% in Q1 2026, selling an estimated $17.3M and leaving 10,948,093 shares worth $98.1M. The position accounts for 1.27% of the portfolio, ranked #5.

SB Investment Advisers (UK) first reported a position in VIR in Q4 2019 and has held it in 26 quarters since. The position peaked at $1.16B in Q1 2021. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • SB Investment Advisers (UK) held 10,948,093 shares of Vir Biotechnology worth $98.1M as of Q1 2026.
  • SB Investment Advisers (UK) sold 2,168,884 Vir Biotechnology shares in Q1 2026, an estimated $17.3M.
  • Vir Biotechnology made up 1.27% of SB Investment Advisers (UK)'s portfolio in Q1 2026, its #5 holding.
  • SB Investment Advisers (UK) first reported a position in Vir Biotechnology in Q4 2019 and has held it in 26 quarters since.
  • SB Investment Advisers (UK)'s Vir Biotechnology position peaked at $1.16B in Q1 2021.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on SB Investment Advisers (UK)'s 13F filing for Q1 2026, filed 18 May 2026.